Bayer to Invest $2.2 Billion in U.S. Pharma Manufacturing Expansion
Novartis AG ADR NVS
News
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal — Update
Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
European Pharma Leaders Push for National Reforms to Boost Investment
Novartis to End ALS Trial Amid String of Study Failures
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
Novartis Down Over 12%, On Pace for Record Percent Decrease — Data Talk
Beneath the surface, the next stock-market leaders are getting ready to break out, says Morgan Stanley
Why the Dow is being dragged down by a Swiss company's bad news
Novartis's Latest Trial Setback Sinks Stock
Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial
Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial
Stocks to Watch: Ionis Pharmaceuticals, Novartis, Corvex
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — 2nd Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint — Update
Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
Novartis Up Nearly 6%, on Pace for Largest Percent Increase Since March 2023 — Data Talk
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
United States